XBRL Proof

XBRL File

Document - Document and Entity Information

Document - Document and Entity Information (USD $)	3 Months Ended
( custom:DocumentAndEntityInformationAbstract [Extension] )
	Mar. 31, 2014	May. 19, 2014



Entity Registrant Name	Artventive Medical Group, Inc.
( dei:EntityRegistrantName )
Entity Central Index Key	0001405249
( dei:EntityCentralIndexKey )
Document Type	10-Q
( dei:DocumentType )
Document Period End Date	2014-03-31
( dei:DocumentPeriodEndDate )
Amendment Flag	false
( dei:AmendmentFlag )
Current Fiscal Year End Date	--12-31
( dei:CurrentFiscalYearEndDate )
Is Entity a Well-known Seasoned Issuer?	No
( dei:EntityWellKnownSeasonedIssuer )
Is Entity a Voluntary Filer?	No
( dei:EntityVoluntaryFilers )
Is Entity's Reporting Status Current?	Yes
( dei:EntityCurrentReportingStatus )
Entity Filer Category	Smaller Reporting Company
( dei:EntityFilerCategory )
Entity Public Float
( dei:EntityPublicFloat )
Entity Common Stock, Shares Outstanding		56,406,286
( dei:EntityCommonStockSharesOutstanding )
Document Fiscal Period Focus	Q1
( dei:DocumentFiscalPeriodFocus )
Document Fiscal Year Focus	2014
( dei:DocumentFiscalYearFocus )

(End Document - Document and Entity Information)

Statement - Balance Sheets (Unaudited)

Statement - Balance Sheets (Unaudited) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Mar. 31, 2014		Dec. 31, 2013





current
( us-gaap:AssetsCurrentAbstract )
Cash and cash equivalents	1,087,618		1,626,521
( us-gaap:CashAndCashEquivalentsAtCarryingValue )
Accounts receivable	10,165		�
( us-gaap:AccountsReceivableGross )
Prepaid expenses	1,048		9,098
( us-gaap:PrepaidExpenseCurrent )
Inventory	280,145		26,903
( us-gaap:InventoryGross )
Total current assets	1,378,976		1,662,522
( us-gaap:AssetsCurrent )
PROPERTY, PLANT and equipment
( us-gaap:PropertyPlantAndEquipmentAbstract )
Office equipment	16,380		16,380
( us-gaap:PropertyPlantAndEquipmentOther )
Accumulated depreciation	(3,075	)	(2,303	)
( us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment )
net property, plant and equipment	13,305		14,077
( us-gaap:PropertyPlantAndEquipmentNet )
other assets
( us-gaap:OtherAssetsAbstract )
Deposits	51,048		51,048
( us-gaap:Deposits )
total other assets	51,048		51,048
( us-gaap:OtherAssets )


Total assets	1,443,329		1,727,647
( us-gaap:Assets )


Liabilities and stockholders’ EQUITY
( us-gaap:StockholdersEquityAbstract )
current LIABILITES
( us-gaap:AccruedLiabilitiesCurrentAbstract )
Accounts payable	144,684		272,509
( us-gaap:AccountsPayableCurrent )
Accrued expenses	695,800		585,800
( us-gaap:AccruedLiabilitiesCurrent )
Notes payable-current portion	11,417		�
( us-gaap:NotesAndLoansPayableCurrent )
Total CURRENT liabilities	851,901		858,309
( us-gaap:LiabilitiesCurrent )


LONG-TERM LIABILITES
( us-gaap:LiabilitiesNoncurrentAbstract )
Notes payable	500,000		�
( us-gaap:NotesPayable )
Less current portion notes payable	(11,417	)	�
( us-gaap:NotesPayableCurrent )
Total LONG-TERM liabilities	488,583		�
( us-gaap:LongTermDebtNoncurrent )


Total LIABILITIES	1,340,484		858,309
( us-gaap:Liabilities )


STOCKHOLDERS EQUITY (DEFICIT
( us-gaap:EquityAbstract )
Common stock, par value $.001, 100,000,000 shares authorized, 56406286 and 55306286 shares issued and outstanding at March 31, 2014 and Decwember 31, 2013, respectively	56,406		55,306
( us-gaap:CommonStockParOrStatedValuePerShare )
Additional paid-in capital	10,045,178		9,056,279
( us-gaap:AdditionalPaidInCapital )
Deficit accumulated during the development stage	(9,998,739	)	(8,242,247	)
( us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage )


Total Stockholders' Equity (Deficit)	102,845		869,338
( us-gaap:StockholdersEquity )
Total Liabilities and Stockholders Equity (Deficit)	1,443,329		1,727,647
( us-gaap:LiabilitiesAndStockholdersEquity )

(End Statement - Balance Sheets (Unaudited))

Statement - Balance Sheets (Parenthetical)

Statement - Balance Sheets (Parenthetical) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Mar. 31, 2014	Dec. 31, 2013







Common stock, par value $.001, authorized	100,000,000	100,000,000
( us-gaap:CommonStockSharesAuthorized )
Common stock, par value $.001, issued and outstanding	56,406,286	55,306,286
( us-gaap:CommonStockSharesIssued )

(End Statement - Balance Sheets (Parenthetical))

Statement - Statements of Operations (Unaudited)

Statement - Statements of Operations (Unaudited) (USD $)	3 Months Ended				86 Months Ended
( us-gaap:IncomeStatementAbstract )
	Mar. 31, 2014		Mar. 31, 2013		Mar. 31, 2014





revenues	10,165		�		10,165
( us-gaap:Revenues )
COST OF GOODS SOLD	10,165		�		10,165
( us-gaap:CostOfGoodsSold )
GROSS PROFIT	�		�		�
( us-gaap:GrossProfit )


operating expenses
( us-gaap:OperatingExpensesAbstract )
Exploration costs	�		�		45,533
( us-gaap:ExplorationCosts )
Research and development	289,522		328,374		5,306,162
( us-gaap:ResearchAndDevelopmentExpense )
Selling, general and administrative	1,466,676		225,247		4,648,934
( us-gaap:SellingGeneralAndAdministrativeExpense )
Depreciation expense	771		583		3,590
( us-gaap:Depreciation )
TOTAL operating expenses	(1,756,969	)	(554,204	)	(10,004,219	)
( us-gaap:OperatingExpenses )
Operating loss before other items and income tax	(1,756,969	)	(554,204	)	(10,004,219	)
( us-gaap:OperatingIncomeLoss )


Other INCOME/(EXPENSE)
( us-gaap:OtherIncomeAndExpensesAbstract )
iNTEREST INCOME	477		235		5,480
( us-gaap:InterestAndDividendIncomeOperating )
Income tax expense (benefit)	�		�		�
( us-gaap:IncomeTaxExpenseBenefit )
net loss availAble to common stockholders	(1,756,492	)	(553,969	)	(9,998,739	)
( us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic )
COMPREHENSIVE LOSS FOR THE PERIOD	(1,756,492	)	(553,969	)	(9,998,739	)
( us-gaap:ComprehensiveIncomeNetOfTax )
basic and diluted loss per common share	(0.03	)	(0.01	)
( us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare )
weighted average shares outstanding	56,022,953		51,222,598
( us-gaap:WeightedAverageBasicSharesOutstandingProForma )

(End Statement - Statements of Operations (Unaudited))

Statement - Statements of Cash Flows (Unaudited)

Statement - Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended				86 Months Ended
( us-gaap:StatementOfCashFlowsAbstract )
	Mar. 31, 2014		Mar. 31, 2013		Mar. 31, 2014







cash flow from operating activities
( us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract )
Net loss	(1,756,492	)	(553,969	)	(9,998,739	)
( us-gaap:NetIncomeLoss )
Adjustments to reconcile net loss to net cash used by operating activities
( us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract )


Non-cash expenses	�		20,169		60,805
( us-gaap:OtherNoncashIncomeExpense )
Depreciation expense	771		583		3,590
( us-gaap:DepreciationAndAmortization )
Issuance of common stock and options for services	�		�		103,482
( us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities )


Changes IN operating assets and liabilities
( us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract )
Accounts receivable	(10,165	)	�		(10,165	)
( us-gaap:IncreaseDecreaseInAccountsReceivable )
Prepaid expenses	8,050		5,000		(1,048	)
( us-gaap:IncreaseDecreaseInPrepaidExpense )
Inventory	(253,242	)	�		(280,145	)
( us-gaap:IncreaseDecreaseInInventories )
Deposits	�		�		(51,048	)
( us-gaap:IncreaseDecreaseInDeposits )
Accounts payable	(127,825	)	138,296		144,684
( us-gaap:IncreaseDecreaseInAccountsPayable )
Payroll taxes payable	�		392		�
( us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities )
Accounts payable – related party	�		�		39,000
( us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties )
Net cash used by operating activities	(2,138,903	)	(389,529	)	(9,989,584	)
( us-gaap:NetCashProvidedByUsedInContinuingOperations )
cash flows from investing activities
( us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract )
Disposal of equipment	�		�		745
( us-gaap:PropertyPlantAndEquipmentDisposals )
Purchase of equipment	�		(3,551	)	(17,623	)
( us-gaap:PaymentsToAcquirePropertyPlantAndEquipment )
NET CASH used BY INVESTING ACTIVITIES	�		(3,551	)	(16,878	)
( us-gaap:NetCashProvidedByUsedInInvestingActivities )
cash flows from financing activities
( us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract )
Issuance of common stock for cash	1,100,000		650,000		10,444,080
( us-gaap:ProceedsFromIssuanceOrSaleOfEquity )
Issuance of notes payable	500,000		�		500,000
( us-gaap:IncreaseDecreaseInNotesPayableCurrent )
Convertible note payable (see Note 4)	�		�		150,000
( us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature )
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,600,000		650,000		11,094,080
( us-gaap:NetCashProvidedByUsedInFinancingActivities )
net increase (decrease) in cash and cash equivalents	(583,903	)	(256,920	)	1,087,618
( us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease )


cash, beginning of period	1,626,521		517,831		�
( us-gaap:Cash )
cash, end of period	1,087,618		774,751		1,087,618
( us-gaap:Cash )


non-cash investing and financing activities
( us-gaap:CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract )
sTOCK ISSUED UPON CONVERSION OF NOTE PAYABLE	�		�		150,000
( us-gaap:RepaymentsOfConvertibleDebt )
forgiveness OF RELATED PARTY NOTE; APPLIED TO PAID IN CAPITAL	�		�		39,000
( us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt )


ACCRUAL OF STOCK ISSUANCE COST	110,000		65,000		695,800
( us-gaap:PaymentsOfStockIssuanceCosts )

(End Statement - Statements of Cash Flows (Unaudited))

Disclosure - Basis of Financial Statement Presentation

Disclosure - Basis of Financial Statement Presentation (USD $)

3 Months Ended

( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )

Mar. 31, 2014

Basis of Financial Statement Presentation

BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensedconsolidated financial statements have been prepared by ArtVentive Medical Group, Inc. “the Company” pursuant to therules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally includedin financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omittedin accordance with such rules and regulations. The information furnished in the interim condensed financial statements includesnormal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentationof such financial statements. Although management believes the disclosures and information presented are adequate to make the informationnot misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with theCompany's audited financial statements and notes thereto included in its Form 10-K filed on March 26, 2014. Operating results forthe three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the fiscal year ended December31, 2014.

( us-gaap:BasisOfAccounting )

(End Disclosure - Basis of Financial Statement Presentation)

Disclosure - Organization

Disclosure - Organization (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2014



Organization	ORGANIZATION The Company was originally incorporatedunder the name of Big Bear Resources, Inc. a USA Company registered in the State of Nevada on January 23, 2007. The Company changedits name to Uranium Plus Resources Inc. on March 21, 2008, and following the acquisition of the assets of ArtVentive, Inc. theCompany changed its name on January 26, 2010, to ArtVentive Medical Group, Inc. The accounting and reporting policies of the Companyconform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end isDecember 31. The Company is a medical device corporation,focused on developing, manufacturing and marketing a family of Endoluminal Occlusion Devices (EOS). Through its innovative, proprietarytechnology the Company has developed unique minimally invasive occlusion devices and procedures, bringing the current interventional,image guided techniques to a new level of sophistication, potentially resolving significant and unaddressed health issues. TheEOS device being developed by the Company targets a substantive market demand in several major clinical areas, including women'shealth, peripheral and neurological vascular disorders, and interventional cardiology procedures. To date, the Company’s activitieshave been committed to the development of the EOS, intellectual property, animal studies, human studies, patent filings, and developinga regulatory strategy for initial clinical indications pertinent to European and FDA submissions and approvals, corporate operationsand the raising of equity capital. The Company conducted the required human clinical studies during 2011 achieving 100% clinicaland procedural success, validating the safety and efficiency of the ArtVentive EOS^TMdevice. The Company received its CE Mark certification for the ArtVentive EOS™ Peripheral device on May 30, 2013. In 2014the Company began commercialization and commenced shipping to its European distributors and preparing the foundation for marketingand sales into the US markets following regulatory approval. On August 3, 2011, the Company incorporatedArtVentive Women’s Health Group, Inc., a wholly owned subsidiary of the Company.
( us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock )

(End Disclosure - Organization)

Disclosure - Significant Accounting Policies

Disclosure - Significant Accounting Policies (USD $)

3 Months Ended

( AccountingPoliciesAbstract )

Mar. 31, 2014

Significant Accounting Policies

3. SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the transactionsof the Company and its subsidiary.

All inter-company accounts and transactions have beeneliminated in consolidation.

DEVELOPMENT STAGE COMPANY

The Company is considered to be inthe development stage as defined in FASC 915-10-05, “Development Stage Entity”. The Company is devoting substantiallyall of its efforts to the execution of its business plan.

USE OF ESTIMATES

The preparation of the Company’sfinancial statements in conformity with accounting principles generally accepted in the United States requires management to makeestimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilitiesat the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual resultscould differ from those estimates. The Company’s periodic filings with the Securities and Exchange Commission include, whereapplicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and futureoperations of the Company.

COMMON STOCK ISSUED FOR OTHER THAN CASH

Services purchased and other transactionssettled in the Company’s common stock and stock options are recorded at the estimated fair value of the stock issued andoptions granted if that value is more readily determinable than the fair value of the consideration received.

EARNINGS PER SHARE OF COMMON STOCK

In accordance with accounting guidancenow codified as FASB ASC Topic 260, “Earnings per Share,” basic earnings (loss) per share is computed by dividing netincome (loss) by weighted average number of shares of common stock outstanding during each period.

Diluted earnings (loss) per shareis computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents andpotentially dilutive securities outstanding during the period.

The Company had the following potential common stock equivalentsat March 31, 2014:

Common stock warrants 4,808,000

Common stock options 105,000

Total common stock equivalents 4,913,000

Since the Company reflected a netloss as of March 31, 2014 and December 31, 2013, the effect of considering any common stock equivalents, if outstanding, wouldhave been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.

The following table sets forth the computation of earningsper share:

March 31, 2014 March 31, 2013

Net income (loss) $ (1,756,492) $ (553,969)

Weighted average common shares outstanding 56,022,95351,222,598

Net (loss) per share $ (0.03) $ (0.01)

PROPERTY AND EQUIPMENT

The Company records property and equipment at cost anduses straight-line depreciation methods.

	Estimated Useful Lives	March 31, 2014	December 31, 2013
Computer equipment Office furniture	5 years 7 years	$ 11,634 4,746	$ 11,634 4,746

Less accumulated depreciation		(3,075)	(2,303)

Net property and equipment		$ 13,305	$ 14,077

FOREIGN CURRENCYTRANSLATIONS

The Company’s functionaland reporting currency is the US dollar. All transactions initiated in other currencies are translated into US dollars using theexchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translatedinto the US dollar at the rate of exchange in effect at the balance sheet date. Unrealized exchange gains and losses arising fromsuch transactions are deferred until realization and are included as a separate component of stockholders’ equity (deficit)as a component of other comprehensive income or loss. Upon realization, the amount deferred is recognized in income in the periodwhen it is realized.

The Company recorded an unrealizedforeign currency translation gain, totaling $0 for the period from January 23, 2007 (Inception) to March 31, 2014, in accumulatedother comprehensive income.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consistof funds on deposit with banks. The Company has no cash equivalents. The Company had funds on deposit of $1,087,618 at March 31,2014.

CONCENTRATION OF RISK

Certain financial instruments, whichsubject the Company to concentration of credit risk, consist of cash. The Company maintains cash balances at financial institutionswhich, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of March 31, 2014 andDecember 31, 2013, the Company had $862,638 and $1,415,194, respectively, in deposits in excess of federally insured limits inits US bank. The Company has not experienced any losses with regard to its bank accounts and believes it is not exposed to anyrisk of loss on its cash in bank accounts.

( us-gaap:SignificantAccountingPoliciesTextBlock )

(End Disclosure - Significant Accounting Policies)

Disclosure - Long Term Debt

Disclosure - Long Term Debt (USD $)

3 Months Ended

( DebtDisclosureAbstract )

Mar. 31, 2014

Long Term Debt

4. LONG-TERM DEBT

The details concerning long-term debt for thethree months ended March 31, 2014, and the year ended December 31, 2013, follow:

	March 31, 2014	December 31, 2013
Note payable to private party, with interest at 3.0%, with interest only payments due December 31, 2014 and June 30, 2015, with the balance, interest and principal, due December 31, 2015	$ 250,000	$ -
Note payable to private party, with interest at 3.0%, with interest only payments due December 31, 2014 and June 30, 2015, with the balance, interest and principal, due December 31, 2015	250,000	-
Total	500,000	-
Less current maturities of long-term debt	(11,417)	-
Noncurrent maturities of long-term debt	$ 488,583	$ -

The Principal Maturities of Notes Payable, by year, are as follows:

2013	$ -
2014	-
2015	$ 500,000
	$ 500,000

( us-gaap:LongTermDebtTextBlock )

(End Disclosure - Long Term Debt)

Disclosure - Share Capital

Disclosure - Share Capital (USD $)	3 Months Ended
( EquityAbstract )
	Mar. 31, 2014



Share Capital	5. SHARE CAPITAL Effective April 22, 2008, theCompany forward-split its issued capital stock on a ratio of 5.8 shares for each prior share. As a result of this transaction,11,078,000 shares were issued. Effective February 12, 2010, the Company forward-split its issued capital stock on a ratio of 1.65a share for each 1 old share. As a result of this transaction 8,442,200 shares were issued. Effective February 19, 2010, 3,767,051shares were issued in a private placement. Consideration for the issue of additional shares has been charged against additionalpaid in capital. The forward stock splits adjustments have been reflected retroactively. Effective April 16, 2010, theBoard of Directors of the Company authorized issuance of 20,000 shares to the members of its Scientific Board at a deemed valueper share of $.90. Effective June 2, 2011, and December30, 2011, the Board of Directors of the Company authorized issuance of 3,888 and 13,611 shares to the former consultants at a deemedvalue per share of $.90. Effective June 26, 2012, 200,000shares were issued in a private placement for the receipt of $200,000. Effective July 5, 2012, the Company’ssubscription agreement was amended to include finder’s fee of 10% of the amount raised in the future in the form of sharesof restricted common stock. Effective September 12, 2012,500,000 shares were issued in a private placement for the receipt of $500,000. On October 3, 2012, October 12,2012, November 5, 2012, and December 12, 2012, 250,000 shares each were issued in a private placement for the total receipt of$1,000,000. Effective February 7, 2013, 500,000shares were issued in a private placement for the receipt of $500,000. Effective March 5, 2013, 150,000shares were issued in a private placement for the receipt of $150,000. Effective April 22, 2013, 100,000shares were issued in a private placement for the receipt of $100,000. Effective June 4, 2013, 308,000shares were issued in a private placement for the receipt of $308,000. Effective July 16, 2013, 300,000shares were issued in a private placement for the receipt of $300,000. Effective August 30, 2013, 200,000shares were issued in a private placement for the receipt of $200,000. Effective September 11, 2013,200,000 shares were issued in a private placement for the receipt of $200,000. Effective September 22, 2013,300,000 shares were issued in a private placement for the receipt of $300,000. Effective October 4, 2013, 300,000shares were issued in a private placement for the receipt of $300,000. Effective November 8, 2013, 400,000shares were issued in a private placement for the receipt of $400,000. Effective December 2, 2013, 400,000shares were issued in a private placement for the receipt of $400,000. Effective December 10, 2013,400,000 shares were issued in a private placement for the receipt of $400,000. Effective December 30, 2013,400,000 shares were issued in a private placement for the receipt of $400,000. Effective January 7, 2014, 400,000shares were issued in a private placement for the receipt of $400,000. Effective February 11, 2014,400,000 shares were issued in a private placement for the receipt of $400,000. Effective March 6, 2014, 300,000shares were issued in a private placement for the receipt of $300,000.
( us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock )

(End Disclosure - Share Capital)

Disclosure - Going Concern and Liquidity

Disclosure - Going Concern and Liquidity (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2014



Going Concern and Liquidity	6. GOING CONCERN AND LIQUIDITYCONSIDERATIONS The accompanying financial statementshave been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realizationof assets and satisfaction of liabilities in the normal course of business. As of March 31, 2014, the Company has a working capitalbalance of $527,075 and an accumulated deficit of $9,998,739. The Company intends to fund operations through equity financing arrangements,which should be sufficient to fund its capital expenditures, working capital and other cash requirements for the next twelve months. The ability of the Company to emergefrom the development stage is dependent upon, among other things, obtaining additional financing to continue operations, research,development and production of its product. In response to these challenges,management intends to raise additional funds through public or private placement offerings. The accompanying financial statementsdo not include any adjustments that might result from the outcome of this uncertainty.
( us-gaap:LiquidityDisclosureTextBlock )

(End Disclosure - Going Concern and Liquidity)

Disclosure - Recently Issued Accounting Pronouncements

Disclosure - Recently Issued Accounting Pronouncements (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2014



Recently Issued Accounting Pronouncements	7. recentlyissued accounting pronouncements Accounting Standards Updates(“ASU”) ASU No. 2014-08 which contain technical corrections to existing guidance or affect guidance to specializedindustries or entities were recently issued. These updates have no current applicability to the Company or their effect on thefinancial statements would not have been significant.
( us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock )

(End Disclosure - Recently Issued Accounting Pronouncements)

Disclosure - Provisions for Income Taxes

Disclosure - Provisions for Income Taxes (USD $)	3 Months Ended
( IncomeTaxDisclosureAbstract )
	Mar. 31, 2014



Provisions for Income Taxes	8. provisionfor income taxes The Company recognizes the taxeffects of transactions in the year in which such transactions enter into the determination of net income, regardless of when reportedfor tax purposes. Deferred taxes are provided in the financial statements under ASC Topic 740 to give effect to the resulting temporarydifferences which may arise from differences in the bases of fixed assets, depreciation methods, allowances, and start-up costsbased on the income taxes expected to be payable in future years. Minimal exploration stage deferred tax assets arising as a resultof net operating loss carry forwards have been offset completely by a valuation allowance due to the uncertainty of their utilizationin future periods. The Company adopted the provisions of ASC Topic 740 Accounting for Uncertainty in Income Taxes, on January23, 2007 (inception date). As a result of the implementation of ASC 740, the Company recognized no increase in the liability forunrecognized tax benefits. Operating loss carry-forwards generatedduring the period of January 23, 2007 (date of inception), through March 31, 2014, of approximately $9,895,257, will begin to expirein 2027. Accordingly, deferred tax assets of approximately $4,159,911 related to net operating loss carry-forwards, and $44,332related to stock-based compensation were offset by the valuation allowance in the same amount. For the three months ended March31, 2014 and 2013, the allowance increased by approximately $752,481 and $235,537, respectively. The Company has no tax positionsat March 31, 2014, or December 31, 2013, for which the ultimate deductibility is highly certain but for which there is uncertaintyabout the timing of such deductibility. The Company recognizes interestaccrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company had no accrualsfor interest and penalties since inception. The statute of limitation is threeyears for Federal tax returns and four years for California state returns.
( us-gaap:IncomeTaxDisclosureTextBlock )

(End Disclosure - Provisions for Income Taxes)

Disclosure - Contractual Obligations

Disclosure - Contractual Obligations (USD $)	3 Months Ended
( DebtDisclosureAbstract )
	Mar. 31, 2014



Contractual Obligations	9. Contractualobligations Effective March1, 2010, the Company entered into Management Agreements with Dr. Leon Rudakov and H. James Graham. Under the termsof the Employment Agreement with its then Chief Executive Officer (CEO) and Chief Technology Officer (CTO), Dr. Rudakov was compensatedwith an annual salary of $120,000, plus benefits. As of February 1, 2011, the base salary was amended to $170,000 per annum toreflect his current positions as the President and CTO. The agreement includes other employment benefits. Effective June 1, 2013,the agreement was amended to reflect a term to December 31, 2018, with an annual salary of $250,000 per annum. Under the terms of a consulting Agreement,effective March 1, 2010, Mr. Jim Graham was compensated with annual base fee of $100,000 per annum, plus benefits. As of February1, 2011, the agreement was amended to reflect Mr. Graham’s current positions of Chief Executive Officer, Chief FinancialOfficer and Chairman of the Board of Directors to reflect a base annual fee of $180,000 per annum. Effective June 1, 2013, theagreement was amended to reflect a term to December 31, 2018, with an annual fee of $260,000 per annum. Effective September 2013, the Company(“Supplier”) executed revised Amended and Restated Distribution Agreements (the “Agreements”) with itscurrent European Distributors (“Distributors”) in the Netherlands, Germany, Austria, Switzerland and Italy. The Agreementsgrant the Distributor the exclusive right to offer for sale and sell the EOS Systems in the respective territories covered by eachof the Agreement. There is a minimum purchase of products included in each of the Agreements. The new Agreements incorporate aquality agreement provision as apart of the original Distribution Agreement.
( us-gaap:DebtDisclosureTextBlock )

(End Disclosure - Contractual Obligations)

Disclosure - Purchase Agreements

Disclosure - Purchase Agreements (USD $)	3 Months Ended
( HealthCareOrganizationsAbstract )
	Mar. 31, 2014



Purchase Agreements	10. PURCHASE AGREEMENT On January 8, 2010, the Company enteredinto an asset purchase agreement with Artventive, Inc. a privately held company. The Company purchased substantially all of theassets of Artventive, Inc. which consisted entirely of patents. The patents were accounted for under SAB Topic 5G using the historicalcost basis of zero. The combination was accounted for under ASC 805 as a business combination.
( us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock )

(End Disclosure - Purchase Agreements)

Disclosure - Warrants and Options

Disclosure - Warrants and Options (USD $)

3 Months Ended

( DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract )

Mar. 31, 2014

Warrants and Options

11. Warrantsand options

During the fiscal year ended December31, 2013, the Company has granted 4,358,000 warrants to purchase shares of Common Stock which all have a 1 year exercise term,of which 3,708,000 remain outstanding at March 31, 2014. During the quarter ended March 31, 2014, 1,100,000 warrants were issued.The issuance of outstanding warrants is detailed below.

Effective April 22 2013, 100,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective June 4, 2013, 308,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective July 16 2013, 300,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective August 30 2013, 200,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective September 11, 2013, 200,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective September 22, 2013, 300,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective October 4 2013, 300,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective October 25, 2013, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective November 8, 2013, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective December 2, 2013, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective December 10, 2013, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective December 30, 2013, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective January 7, 2014, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective February 11, 2014, 400,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective March 6, 2014, 300,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

The Company valued all warrantsutilizing a Black-Scholes option-pricing model and the fair value was recorded in additional paid-in capital.

The following is a summary of theCompany’s warrant activity:

	Warrants	Weighted Average Exercise Price
Exercisable – December 31, 2012	1,500,000	$ 1.50
Granted-2013	4,358,000	$ 1.50
Exercised-2013	-	-
Forfeited-2013	(1,500,000)	$ 1.50
Outstanding – December 31, 2013	4,358,000	$ 1.50
Exercisable – December 31, 2013	4,358,000	$ 1.50

	Warrants	Weighted Average Exercise Price
Granted-2014 (at March 31, 2014)	1,100,000	$ 1.50
Exercised-2014 (at March 31, 2014)	-	-
Forfeited-2014 (at March 31, 2014)	(650,000)	$ 1.50
Outstanding – March 31, 2014	4,808,000	$ 1.50
Exercisable – March 31, 2014	4,808,000	$ 1.50

Warrants outstanding and exercisableat March 31, 2014 are as follows:

Warrants Outstanding				Warrants Exercisable
	Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life (in Years)	Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.50	100,000	0.06 years	$	1.50		100,000	$	1.50
$	1.50	308,000	0.18 years	$	1.50		308,000	$	1.50
$	1.50	300,000	0.29 years	$	1.50		300,000	$	1.50
$	1.50	200,000	0.42 years	$	1.50		200,000	$	1.50
$	1.50	200,000	0.45 years	$	1.50		200,000	$	1.50
$	1.50	300,000	0.48 years	$	1.50		300,000	$	1.50
$	1.50	300,000	0.51 years	$	1.50		300,000	$	1.50
$	1.50	400,000	0.56 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.61 years	$	1.50		400,000	$	1.50
$	1.50	400.000	0.66 years	$	1.50		400,000	$	1.50
$	1.50	400.000	0.68 years	$	1.50		400,000	$	1.50
$	1.50	400.000	0.73 years	$	1.50		400,000	$	1.50
$	1.50	400.000	0.76 years	$	1.50		400,000	$	1.50
$	1.50	400.000	0.85 years	$	1.50		400,000	$	1.50
$	1.50	300.000	0.93 years	$	1.50		300,000	$	1.50

Effective November 2, 2010 theBoard of Directors of the Company granted 50,000 non-statutory stock options to a former consultant at an exercise price of $.001per share with the vesting date of November 2, 2013 and an expiration date of November 2, 2016.

Effective February 1, 2013 theBoard of Directors of the Company granted 20,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013 theBoard of Directors of the Company granted 5,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013 theBoard of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.

Effective March 1, 2013 the Boardof Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 pershare with the vesting date of March 1, 2013 and an expiration date of March 1, 2018.

Effective December 27, 2013 theBoard of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of December 27, 2013 and an expiration date of December 27, 2018.

During the period that the optionswere issued, the Company had no public trading activity for the Company’s common stock. However, the majority shareholdersold in private transactions shares at $.90 per share. In order to value the Company’s options, the Company chose to usethe minimum value method, even though the Company is a public company since there was no measurable trading activity. The fairvalue of the options was recorded in additional paid-in capital.

Options outstanding and exercisableat March 31, 2014 are as follows:

	Options	Weighted Average Exercise Price
Exercisable – December 31, 2012	50,000	$ 0.001
Granted-2013	55,000	$ 1.00
Exercised-2013	-	-
Forfeited-2013	-	-
Outstanding – December 31, 2013	105,000	$ 0.524
Exercisable – December 31, 2012	105,000	$ 0.524
	Options	Weighted Average Exercise Price
Granted-2014 (at March 31, 2014)	-	$ -
Exercised-2014 (at March 31, 2014)	-	-
Forfeited-2014 (at March 31, 2014)	-	$ -
Outstanding – March 31, 2014	105,000	$ 0.524
Exercisable – March 31, 2014	105,000	$ 0.524

Options outstandingand exercisable at March 31, 2014 are as follows:

Options Outstanding							Options Exercisable
	Range of Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$		0.001		50,000		1.59 years	$	0.001		50,000		$	0.001
$		1.000		35,000		3.84 years	$	1.000		35,000		$	1.000
$		1.000		10,000		3.92 years	$	1.000		10,000		$	1.000
$		1.000		10,000		4.74 years	$	1.000		10,000		$	1.000

( us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock )

(End Disclosure - Warrants and Options)

Disclosure - Subsequent Events

Disclosure - Subsequent Events (USD $)	3 Months Ended
( SubsequentEventsAbstract )
	Mar. 31, 2014



Subsequent Events	12.SUBSEQUENT EVENTS The Company evaluated all eventsor transactions that occurred after March 31, 2014, up through the date these consolidated financial statements were issued.
( us-gaap:SubsequentEventsTextBlock )

(End Disclosure - Subsequent Events)

Disclosure - Significant Accounting Policies (Policies)

Disclosure - Significant Accounting Policies (Policies) (USD $)

3 Months Ended

( AccountingPoliciesAbstract )

Mar. 31, 2014

Principles of Consolidation

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the transactionsof the Company and its subsidiary.

All inter-company accounts and transactions have beeneliminated in consolidation.

( us-gaap:ConsolidationPolicyTextBlock )

DEVELOPMENT STAGE COMPANY

DEVELOPMENT STAGE COMPANY

( us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock )

USE OF ESTIMATES

USE OF ESTIMATES

( us-gaap:UseOfEstimates )

COMMON STOCK ISSUED FOR OTHER THAN CASH

COMMON STOCK ISSUED FOR OTHER THAN CASH

( us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock )

EARNINGS PER SHARE OF COMMON STOCK

EARNINGS PER SHARE OF COMMON STOCK

The Company had the following potential common stock equivalentsat March 31, 2014:

Common stock warrants 4,808,000

Common stock options 105,000

Total common stock equivalents 4,913,000

The following table sets forth the computation of earningsper share:

March 31, 2014 March 31, 2013

Net income (loss) $ (1,756,492) $ (553,969)

Weighted average common shares outstanding 56,022,95351,222,598

Net (loss) per share $ (0.03) $ (0.01)

( us-gaap:EarningsPerSharePolicyTextBlock )

Property and Equipment

PROPERTY AND EQUIPMENT

The Company records property and equipment at cost anduses straight-line depreciation methods.

	Estimated Useful Lives	March 31, 2014	December 31, 2013
Computer equipment Office furniture	5 years 7 years	$ 11,634 4,746	$ 11,634 4,746

Less accumulated depreciation		(3,075)	(2,303)

Net property and equipment		$ 13,305	$ 14,077

( us-gaap:PropertyPlantAndEquipmentPolicyTextBlock )

FOREIGN CURRENCY TRANSLATIONS

FOREIGN CURRENCYTRANSLATIONS

The Company recorded an unrealizedforeign currency translation gain, totaling $0 for the period from January 23, 2007 (Inception) to March 31, 2014, in accumulatedother comprehensive income.

( us-gaap:ForeignCurrencyDisclosureTextBlock )

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consistof funds on deposit with banks. The Company has no cash equivalents. The Company had funds on deposit of $1,087,618 at March 31,2014.

( us-gaap:CashAndCashEquivalentsPolicyTextBlock )

CONCENTRATION OF RISK

CONCENTRATION OF RISK

( us-gaap:ConcentrationRiskDisclosureTextBlock )

(End Disclosure - Significant Accounting Policies (Policies))

Disclosure - Long Term Debt (Tables)

Disclosure - Long Term Debt (Tables) (USD $)

3 Months Ended

( DebtDisclosureAbstract )

Mar. 31, 2014

Long Term Debt

	March 31, 2014	December 31, 2013
Note payable to private party, with interest at 3.0%, with interest only payments due December 31, 2014 and June 30, 2015, with the balance, interest and principal, due December 31, 2015	$ 250,000	$ -
Note payable to private party, with interest at 3.0%, with interest only payments due December 31, 2014 and June 30, 2015, with the balance, interest and principal, due December 31, 2015	250,000	-
Total	500,000	-
Less current maturities of long-term debt	(11,417)	-
Noncurrent maturities of long-term debt	$ 488,583	$ -

( us-gaap:ScheduleOfDebtTableTextBlock )

(End Disclosure - Long Term Debt (Tables))

Disclosure - Going Concern and Liquidity (Details Narrative)

Disclosure - Going Concern and Liquidity (Details Narrative) (USD $)
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )




Accumulated Deficit	$9,998,739.
( us-gaap:EffectOnRetainedEarningsAccumulatedDeficitDueToChangeInMeasurementDateBeforeTax )

(End Disclosure - Going Concern and Liquidity (Details Narrative))

Contexts

ID	Period	CIK
From2014-01-01to2014-03-31	2014-01-01 - 2014-03-31	0001405249
AsOf2014-05-19	2014-05-19	0001405249
AsOf2014-03-31	2014-03-31	0001405249
AsOf2013-12-31	2013-12-31	0001405249
From2013-01-01to2013-03-31	2013-01-01 - 2013-03-31	0001405249
From2007-01-23to2014-03-31	2007-01-23 - 2014-03-31	0001405249
AsOf2012-12-31	2012-12-31	0001405249
AsOf2013-03-31	2013-03-31	0001405249
AsOf2007-01-22	2007-01-22	0001405249

(End Contexts)

Elements

Element		Data Type

AccountingPoliciesAbstract		xbrli:stringItemType	Duration	—

DebtDisclosureAbstract		xbrli:stringItemType	Duration	—

DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract		xbrli:stringItemType	Duration	—

EquityAbstract		xbrli:stringItemType	Duration	—

HealthCareOrganizationsAbstract		xbrli:stringItemType	Duration	—

IncomeTaxDisclosureAbstract		xbrli:stringItemType	Duration	—

OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract		xbrli:stringItemType	Duration	—

SubsequentEventsAbstract		xbrli:stringItemType	Duration	—

custom:DocumentAndEntityInformationAbstract		xbrli:stringItemType	Duration	—	Yes (Auto)

dei:AmendmentFlag		xbrli:booleanItemType	Duration	—
	If the value is true, then the document is an amendment to previously-filed/accepted document.
dei:CurrentFiscalYearEndDate		xbrli:gMonthDayItemType	Duration	—
	End date of current fiscal year in the format --MM-DD.
dei:DocumentFiscalPeriodFocus		dei:fiscalPeriodItemType	Duration	—
	This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
dei:DocumentFiscalYearFocus		xbrli:gYearItemType	Duration	—
	This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
dei:DocumentPeriodEndDate		xbrli:dateItemType	Duration	—
	The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
dei:DocumentType		dei:submissionTypeItemType	Duration	—
	The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
dei:EntityCentralIndexKey		dei:centralIndexKeyItemType	Duration	—
	A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
dei:EntityCommonStockSharesOutstanding		xbrli:sharesItemType	Instant	—
	Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
dei:EntityCurrentReportingStatus		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityFilerCategory		dei:filerCategoryItemType	Duration	—
	Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityPublicFloat		xbrli:monetaryItemType	Instant	Credit
	State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
dei:EntityRegistrantName		xbrli:normalizedStringItemType	Duration	—
	The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
dei:EntityVoluntaryFilers		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
dei:EntityWellKnownSeasonedIssuer		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
us-gaap:AccountsPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccountsReceivableGross		xbrli:monetaryItemType	Instant	Debit
	For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.
us-gaap:AccruedLiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccruedLiabilitiesCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		xbrli:monetaryItemType	Instant	Credit
	Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
us-gaap:AdditionalPaidInCapital		xbrli:monetaryItemType	Instant	Credit
	Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities		xbrli:monetaryItemType	Duration	Debit
	The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature		xbrli:monetaryItemType	Duration	Credit
	Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt		xbrli:monetaryItemType	Duration	Credit
	Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.
us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:Assets		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsCurrent		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:BasisOfAccounting		nonnum:textBlockItemType	Duration	—
	The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for prepaid health care service provider's significant business and contractual arrangements with hospitals, physicians, or other associated entities.
us-gaap:Cash		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsAtCarryingValue		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease		xbrli:monetaryItemType	Duration	Debit
	Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
us-gaap:CashAndCashEquivalentsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
us-gaap:CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract		xbrli:stringItemType	Duration	—

us-gaap:CommonStockParOrStatedValuePerShare		num:perShareItemType	Instant	—
	Face amount or stated value per share of common stock.
us-gaap:CommonStockSharesAuthorized		xbrli:sharesItemType	Instant	—
	The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
us-gaap:CommonStockSharesIssued		xbrli:sharesItemType	Instant	—
	Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
us-gaap:ComprehensiveIncomeNetOfTax		xbrli:monetaryItemType	Duration	Credit
	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
us-gaap:ConcentrationRiskDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
us-gaap:ConsolidationPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
us-gaap:CostOfGoodsSold		xbrli:monetaryItemType	Duration	Debit
	Total costs related to goods produced and sold during the reporting period.
us-gaap:DebtDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
us-gaap:Deposits		xbrli:monetaryItemType	Instant	Credit
	The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.
us-gaap:Depreciation		xbrli:monetaryItemType	Duration	Debit
	The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
us-gaap:DepreciationAndAmortization		xbrli:monetaryItemType	Duration	Debit
	The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage		xbrli:monetaryItemType	Instant	Debit
	Cumulative net losses reported during the development stage.
us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for all or part of the detailed information required for development stage enterprises. The information may also be disclosed on an element-by-element basis. Information may include an identification of the current or prior year financial statements of the entity, its development stage subsidiaries, or its investees as those of one or more development stage enterprises; a description of the nature of the development stage activities in which each enterprise is engaged; and in the first fiscal year in which each enterprise is no longer considered a development stage enterprise, a statement that in prior years the enterprise had been in the development stage.
us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.
us-gaap:EarningsPerSharePolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
us-gaap:EffectOnRetainedEarningsAccumulatedDeficitDueToChangeInMeasurementDateBeforeTax		xbrli:monetaryItemType	Duration	Debit
	Before tax adjustment decreasing or increasing retained earnings due to a change in the measurement date for a defined benefit pension and other postretirement plan in the initial application of the measurement provision of FAS 158.
us-gaap:EquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:ExplorationCosts		xbrli:monetaryItemType	Duration	Debit
	The capitalized costs incurred during the period (excluded from amortization) in identifying areas that may warrant examination and in examining specific areas that are considered to have prospects of containing oil and gas reserves, including costs of drilling exploratory wells and exploratory-type stratigraphic test wells. Exploration costs may be incurred both before acquiring the related property (sometimes referred to in part as prospecting costs) and after acquiring the property. Principal types of exploration costs, which include depreciation and applicable operating costs of support equipment and facilities and other costs of exploration activities, are: costs of topographical, geographical and geophysical studies, rights of access to properties to conduct those studies, and salaries and other expenses of geologists, geophysical crews, and others conducting those studies. Collectively, these are sometimes referred to as geological and geophysical or "G&G" costs. Exploration costs also include costs o
us-gaap:ForeignCurrencyDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.
us-gaap:GrossProfit		xbrli:monetaryItemType	Duration	Credit
	Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare		num:perShareItemType	Duration	—
	The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
us-gaap:IncomeStatementAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncomeTaxDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
us-gaap:IncomeTaxExpenseBenefit		xbrli:monetaryItemType	Duration	Debit
	Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
us-gaap:IncreaseDecreaseInAccountsPayable		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
us-gaap:IncreaseDecreaseInAccountsReceivable		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
us-gaap:IncreaseDecreaseInDeposits		xbrli:monetaryItemType	Duration	Debit
	The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
us-gaap:IncreaseDecreaseInInventories		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
us-gaap:IncreaseDecreaseInNotesPayableCurrent		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.
us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncreaseDecreaseInPrepaidExpense		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
us-gaap:InterestAndDividendIncomeOperating		xbrli:monetaryItemType	Duration	Credit
	Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.
us-gaap:InventoryGross		xbrli:monetaryItemType	Instant	Debit
	Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
us-gaap:Liabilities		xbrli:monetaryItemType	Instant	Credit
	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
us-gaap:LiabilitiesAndStockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
us-gaap:LiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
us-gaap:LiabilitiesNoncurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiquidityDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substa
us-gaap:LongTermDebtNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
us-gaap:LongTermDebtTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for long-term debt.
us-gaap:NetCashProvidedByUsedInContinuingOperations		xbrli:monetaryItemType	Duration	—
	The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.
us-gaap:NetCashProvidedByUsedInFinancingActivities		xbrli:monetaryItemType	Duration	Debit
	Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetCashProvidedByUsedInInvestingActivities		xbrli:monetaryItemType	Duration	Debit
	Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetIncomeLoss		xbrli:monetaryItemType	Duration	Credit
	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic		xbrli:monetaryItemType	Duration	Credit
	Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
us-gaap:NotesAndLoansPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.
us-gaap:NotesPayable		xbrli:monetaryItemType	Instant	Credit
	Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
us-gaap:NotesPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
us-gaap:OperatingExpenses		xbrli:monetaryItemType	Duration	Debit
	Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
us-gaap:OperatingExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OperatingIncomeLoss		xbrli:monetaryItemType	Duration	Credit
	The net result for the period of deducting operating expenses from operating revenues.
us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
us-gaap:OtherAssets		xbrli:monetaryItemType	Instant	Debit
	The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.
us-gaap:OtherAssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherIncomeAndExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherNoncashIncomeExpense		xbrli:monetaryItemType	Duration	Credit
	Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.
us-gaap:PaymentsOfStockIssuanceCosts		xbrli:monetaryItemType	Duration	Credit
	The cash outflow for cost incurred directly with the issuance of an equity security.
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment		xbrli:monetaryItemType	Duration	Credit
	The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
us-gaap:PrepaidExpenseCurrent		xbrli:monetaryItemType	Instant	Debit
	Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
us-gaap:ProceedsFromIssuanceOrSaleOfEquity		xbrli:monetaryItemType	Duration	Debit
	The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
us-gaap:PropertyPlantAndEquipmentAbstract		xbrli:stringItemType	Duration	—

us-gaap:PropertyPlantAndEquipmentDisposals		xbrli:monetaryItemType	Duration	Credit
	Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
us-gaap:PropertyPlantAndEquipmentNet		xbrli:monetaryItemType	Instant	Debit
	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
us-gaap:PropertyPlantAndEquipmentOther		xbrli:monetaryItemType	Instant	Debit
	Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
us-gaap:PropertyPlantAndEquipmentPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
us-gaap:RepaymentsOfConvertibleDebt		xbrli:monetaryItemType	Duration	Credit
	The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
us-gaap:ResearchAndDevelopmentExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
us-gaap:Revenues		xbrli:monetaryItemType	Duration	Credit
	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
us-gaap:ScheduleOfDebtTableTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
us-gaap:SellingGeneralAndAdministrativeExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
us-gaap:SignificantAccountingPoliciesTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for all significant accounting policies of the reporting entity.
us-gaap:StatementOfCashFlowsAbstract		xbrli:stringItemType	Duration	—

us-gaap:StatementOfFinancialPositionAbstract		xbrli:stringItemType	Duration	—

us-gaap:StockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
us-gaap:StockholdersEquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:SubsequentEventsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
us-gaap:UseOfEstimates		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
us-gaap:WeightedAverageBasicSharesOutstandingProForma		xbrli:sharesItemType	Duration	—
	The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
Total Elements					129
Total Non-Abstract Elements					102
Total Extension Elements					1
Percent Extended					0%
Percent Extended (excluding abstracts)					0%

(End Elements)